Nanobiotix S.A.
NBTX
$3.39
$0.24117.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -158.54% | -159.72% | -- | -- | -- |
| Total Other Revenue | -55.19% | -54.29% | -6.13% | -3.90% | -12.67% |
| Total Revenue | -149.57% | -150.57% | 178.93% | 185.55% | 906.12% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -149.57% | -150.57% | 178.93% | 185.55% | 906.12% |
| SG&A Expenses | -14.19% | -12.46% | -1.40% | 0.94% | 43.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.98% | -10.21% | 13.20% | 15.89% | 38.09% |
| Operating Income | -3,988.24% | -4,066.11% | 8.31% | 6.13% | 105.77% |
| Income Before Tax | -299.22% | -307.25% | 23.53% | 21.71% | 60.56% |
| Income Tax Expenses | -136.35% | -137.05% | 4,743.75% | 4,787.50% | 3,050.00% |
| Earnings from Continuing Operations | -294.83% | -302.77% | 23.03% | 21.20% | 60.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -294.83% | -302.77% | 23.03% | 21.20% | 60.16% |
| EBIT | -3,988.24% | -4,066.11% | 8.31% | 6.13% | 105.77% |
| EBITDA | -3,212.83% | -3,275.32% | 6.70% | 4.49% | 107.79% |
| EPS Basic | -223.24% | -229.89% | 42.77% | 41.42% | 64.27% |
| Normalized Basic EPS | -853.59% | -872.68% | 45.07% | 43.73% | 83.42% |
| EPS Diluted | -217.21% | -223.59% | 42.77% | 41.42% | 63.49% |
| Normalized Diluted EPS | -853.59% | -872.68% | 45.07% | 43.73% | 83.42% |
| Average Basic Shares Outstanding | 22.12% | 22.12% | 34.50% | 34.50% | 11.51% |
| Average Diluted Shares Outstanding | 22.12% | 22.12% | 34.50% | 34.50% | 11.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |